Evidence map›Paper›PMID 30700422›Full record

ArticleAnnals of the rheumatic diseases2020

Risk of severe infection following rituximab and the efficacy of antimicrobial prophylaxis.

Zachary Scott Wallace, Hyon Choi, John H Stone

Abstract readLetterComment
PubMed Publisher
In one paragraph

Article in Annals of the rheumatic diseases, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Updates in ANCA-associated vasculitis.European journal of rheumatology · 2022
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors.

Zachary Scott WallaceRheumatology Unit, Division of Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Boston, USA zswallace@mgh.harvard.edu.ORCID 0000-0003-4708-7038
Hyon ChoiRheumatology Unit, Division of Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Boston, USA.
John H StoneRheumatology Unit, Division of Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Boston, USA.

Funding

Impact of ANCA Type and Rituximab vs. Cyclophosphamide on Cardiovascular Risk, Mortality, and Quality-Adjusted Life Years inANCA-Associated VasculitisK23AR073334 · NIAMS · MASSACHUSETTS GENERAL HOSPITAL · PI WALLACE, ZACHARY SCOTT · 2018 to 2022
$948k
NIAMS NIH HHS K23 AR073334
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Anti-Infective AgentsInfectionsCytoplasmHumansRituximabTrimethoprim, Sulfamethoxazole Drug CombinationAnti-Infective AgentsRituximabTrimethoprim, Sulfamethoxazole Drug Combinationepidemiologyinfectionssystemic vasculitis

Identifiers

PMID30700422

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.